Search Results 811-820 of 16948 for monoclonal antibody

  1. Health Topics - Mayo Clinic News Network

    Mayo Clinic Q&A podcast: Herd immunity, antibodies and COVID-19. Jennifer O'Hara. July 31, 2020. Sharing Mayo Clinic. Voices of Mayo: Matthew Horace on Race in ...

  2. High blood protein Causes - Mayo Clinic

    https://www.niddk.nih.gov/health-information/kidney-disease/amyloidosis. Accessed Sept. 16, 2024. Monoclonal gammopathy of undetermined significance (MGUS).

  3. Cholangiocarcinoma (Bile Duct Cancer) Clinical Trials - Mayo Clinic Research

    Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor ...

  4. Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies - Mayo Clinic

    Known intolerance to CD20 monoclonal antibody therapy. History of primary central nervous system (CNS) lymphoma or CNS neoplastic disease. Platelet count ...

  5. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or ...

  6. Overview - B-Cell Lymphoproliferative Disorders - Mayo Clinic Research

    The Slager B-Cell Lymphoproliferative Disorders Lab at Mayo Clinic studies the genetic epidemiology of chronic lymphocytic leukemia (CLL), monoclonal B-cell ...

  7. A Multicenter Assessment of ALD403 in Chronic Migraine - Mayo Clinic

    Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial); Previously dosed with ALD403 or any ...

  8. Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma - Mayo Clinic

    ... monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled ...

  9. Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM - Mayo Clinic

    Active secondary malignancy; Prior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug, or not recovered from adverse effects ...

  10. A Study to Evaluate Immune-related Biomarkers for Pathological Response in Stage II-III HER2-positive Breast Cancer - Mayo Clinic

    NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule ...